FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387230487> ?p ?o ?g. }

• W4387230487 abstract "BACKGROUND Immune checkpoint inhibitors can cause various immune-related adverse events (irAEs). This study aimed to evaluate the association between the incidence of irAEs and oncological outcomes of metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab as first-line therapy. PATIENTS AND METHODS We retrospectively analyzed data from 69 patients with mRCC treated with nivolumab plus ipilimumab as first-line therapy between September 2018 and September 2021 at four institutions. Cox regression analyses were performed to investigate the important factors affecting overall survival (OS) in patients with mRCC treated with nivolumab plus ipilimumab as first-line therapy. RESULTS During observation with a median follow-up of 9.1 months, the median OS was not reached, while the median progression-free survival was 6.0 months. Patients with irAEs had significantly prolonged OS and progression-free survival than those without irAEs (p = 0.012 and 0.002, respectively). Multivariate analysis showed that three independent factors, including C-reactive protein (CRP), irAEs, and performance status (PS), were significantly associated with OS (p = 0.04, 0.02, and 0.01, respectively). The patients were subsequently divided into three groups as follows: group 1, 20 patients with all three independent OS predictors; group 2, 18 patients with irAE predictors alone or two positive independent OS predictors (irAEs + CRP or irAEs + PS); group 3, 31 patients with three negative independent OS predictors. OS varied significantly among the three groups (p = 0.004). CONCLUSION The appearance of irAEs could predict OS in patients with mRCC treated with nivolumab plus ipilimumab as the first-line therapy. Micro Abstract A novel stratification system based on the positive numbers of independent overall survival (OS) predictors related immune-related adverse events (irAEs) may help guide decision-making for patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab as first-line therapy." @default.
• W4387230487 created "2023-10-02" @default.
• W4387230487 creator A5002217801 @default.
• W4387230487 creator A5003587912 @default.
• W4387230487 creator A5006776440 @default.
• W4387230487 creator A5007413510 @default.
• W4387230487 creator A5015650717 @default.
• W4387230487 creator A5021692335 @default.
• W4387230487 creator A5022320757 @default.
• W4387230487 creator A5024205770 @default.
• W4387230487 creator A5025622753 @default.
• W4387230487 creator A5029382212 @default.
• W4387230487 creator A5029568633 @default.
• W4387230487 creator A5030580122 @default.
• W4387230487 creator A5031393351 @default.
• W4387230487 creator A5038102022 @default.
• W4387230487 creator A5039665271 @default.
• W4387230487 creator A5040122887 @default.
• W4387230487 creator A5043187078 @default.
• W4387230487 creator A5045104199 @default.
• W4387230487 creator A5045922337 @default.
• W4387230487 creator A5058151593 @default.
• W4387230487 creator A5062447398 @default.
• W4387230487 creator A5064917014 @default.
• W4387230487 creator A5065751906 @default.
• W4387230487 creator A5071012389 @default.
• W4387230487 creator A5071593174 @default.
• W4387230487 creator A5073538169 @default.
• W4387230487 creator A5075132299 @default.
• W4387230487 creator A5078064024 @default.
• W4387230487 creator A5081087358 @default.
• W4387230487 date "2023-10-01" @default.
• W4387230487 modified "2023-10-14" @default.
• W4387230487 title "Prognostic impact of immune-related adverse events as first-line therapy for metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: A multicenter retrospective study" @default.
• W4387230487 cites W1893566975 @default.
• W4387230487 cites W1994295819 @default.
• W4387230487 cites W2002673340 @default.
• W4387230487 cites W2019607817 @default.
• W4387230487 cites W2022169059 @default.
• W4387230487 cites W2052041234 @default.
• W4387230487 cites W2099752220 @default.
• W4387230487 cites W2105057287 @default.
• W4387230487 cites W2121960517 @default.
• W4387230487 cites W2222086386 @default.
• W4387230487 cites W2473218705 @default.
• W4387230487 cites W2549481046 @default.
• W4387230487 cites W2592144107 @default.
• W4387230487 cites W2597772749 @default.
• W4387230487 cites W2606604537 @default.
• W4387230487 cites W2786816161 @default.
• W4387230487 cites W2792937256 @default.
• W4387230487 cites W2802370184 @default.
• W4387230487 cites W2809615201 @default.
• W4387230487 cites W2911812451 @default.
• W4387230487 cites W2913745075 @default.
• W4387230487 cites W2917602796 @default.
• W4387230487 cites W2928025315 @default.
• W4387230487 cites W2942674623 @default.
• W4387230487 cites W2947771252 @default.
• W4387230487 cites W2969712092 @default.
• W4387230487 cites W2985979810 @default.
• W4387230487 cites W2986757102 @default.
• W4387230487 cites W3009081800 @default.
• W4387230487 cites W3042095160 @default.
• W4387230487 cites W3084419359 @default.
• W4387230487 cites W3107453141 @default.
• W4387230487 cites W3131063362 @default.
• W4387230487 cites W3134949580 @default.
• W4387230487 cites W3160691658 @default.
• W4387230487 cites W3165613085 @default.
• W4387230487 cites W3174164643 @default.
• W4387230487 cites W3175085288 @default.
• W4387230487 cites W4205224142 @default.
• W4387230487 cites W4207018755 @default.
• W4387230487 cites W4226442571 @default.
• W4387230487 cites W4302305168 @default.
• W4387230487 cites W4310072450 @default.
• W4387230487 doi "https://doi.org/10.1016/j.clgc.2023.09.007" @default.
• W4387230487 hasPublicationYear "2023" @default.
• W4387230487 type Work @default.
• W4387230487 citedByCount "0" @default.
• W4387230487 crossrefType "journal-article" @default.
• W4387230487 hasAuthorship W4387230487A5002217801 @default.
• W4387230487 hasAuthorship W4387230487A5003587912 @default.
• W4387230487 hasAuthorship W4387230487A5006776440 @default.
• W4387230487 hasAuthorship W4387230487A5007413510 @default.
• W4387230487 hasAuthorship W4387230487A5015650717 @default.
• W4387230487 hasAuthorship W4387230487A5021692335 @default.
• W4387230487 hasAuthorship W4387230487A5022320757 @default.
• W4387230487 hasAuthorship W4387230487A5024205770 @default.
• W4387230487 hasAuthorship W4387230487A5025622753 @default.
• W4387230487 hasAuthorship W4387230487A5029382212 @default.
• W4387230487 hasAuthorship W4387230487A5029568633 @default.
• W4387230487 hasAuthorship W4387230487A5030580122 @default.
• W4387230487 hasAuthorship W4387230487A5031393351 @default.
• W4387230487 hasAuthorship W4387230487A5038102022 @default.
• W4387230487 hasAuthorship W4387230487A5039665271 @default.
• W4387230487 hasAuthorship W4387230487A5040122887 @default.
• W4387230487 hasAuthorship W4387230487A5043187078 @default.
• W4387230487 hasAuthorship W4387230487A5045104199 @default.

• next